BDPARIB 200mg

Bdparib 200mg tablet contains rucaparib as its active ingredient. This anti-cancer medication falls under the category of PARP (poly ADP-ribose polymerase) inhibitors. It is utilized to sustain the response to other therapies for specific forms of ovarian cancer, fallopian tube cancer (which is the tube that carries eggs from the ovaries to the uterus), and primary peritoneal cancer (the tissue layer lining the abdomen) that has recurred in adults who have previously had a complete or partial response to other chemotherapy treatments.

Additionally, it is prescribed for certain cancer types in individuals with specific gene (BRCA) alterations who have undergone at least two other chemotherapy regimens. It is also recommended as maintenance therapy right after chemotherapy that has led to tumor reduction. Avoid taking Bdparib 200mg tablet if you have an allergy to Bdparib or any of its components. This medication may lead to low blood counts; therefore, your healthcare provider will recommend specific blood tests before and monthly throughout the treatment.

Notify your doctor if you experience nausea, vomiting, diarrhea, or abdominal discomfort during treatment, as this medication may impact your stomach or intestines. Bdparib 200mg tablet is not suitable for children under 18 years of age. Inform your physician if you are pregnant, breastfeeding, suspecting, or planning a pregnancy while undergoing treatment with this medication. Women of reproductive age should employ effective contraception during the treatment.